GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (LTS:0SAN) » Definitions » ROE % Adjusted to Book Value

Sandoz Group AG (LTS:0SAN) ROE % Adjusted to Book Value : 1.88% (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG ROE % Adjusted to Book Value?

Sandoz Group AG's ROE % for the quarter that ended in Jun. 2024 was 3.59%. Sandoz Group AG's PB Ratio for the quarter that ended in Jun. 2024 was 1.91. Sandoz Group AG's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 was 1.88%.


Sandoz Group AG ROE % Adjusted to Book Value Historical Data

The historical data trend for Sandoz Group AG's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG ROE % Adjusted to Book Value Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
ROE % Adjusted to Book Value
- 0.54

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
ROE % Adjusted to Book Value - - -2.35 1.88

Competitive Comparison of Sandoz Group AG's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's ROE % Adjusted to Book Value falls into.



Sandoz Group AG ROE % Adjusted to Book Value Calculation

Sandoz Group AG's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.85% / 1.56
=0.54%

Sandoz Group AG's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=3.59% / 1.91
=1.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sandoz Group AG ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG Business Description

Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines